Aibo Medical Robotics Successfully Completes Cross-Departmental Animal Trials for Cerebrovascular and Coronary Interventions

Recently, the vascular interventional surgical robot independently developed by Shenzhen Aibo Medical Robot Co., Ltd. (hereinafter referred to as “Aibo Medical Robot”) successfully completed several animal procedures involving interventional angiography for two cross-departmental indications: cerebrovascular and coronary interventions. Two medical teams, led by Academician Ge Junbo from the Department of Cardiology at Shanghai Zhongshan Hospital (Principal Investigator for cardiac intervention) and Professor Liu Jianmin from the Cerebrovascular Disease Center at Changhai Hospital (Principal Investigator for neurointervention), jointly participated in this two-week animal experiment and training program.

Professor Liu Jianmin of the Cerebrovascular Disease Center at Changhai Hospital Conducts Animal Experiments

During animal surgeries, the circulating nurse can transport and install the interventional surgical robot’s actuator onto the operating table via a transfer trolley in under one minute. The lead surgeon sits at the console and performs the procedure using Aibo Medical Robot’s proprietary control terminal, which is designed based on the concept of natural interaction. Throughout the surgery, the lead surgeon conducts teleoperation through the control terminal, coordinating with the actuator to manipulate guidewires and catheters. This enables the smooth execution of various superselective endovascular interventional maneuvers, delivering the catheter to different sites for corresponding angiographic examinations. The entire surgical procedure can be completed within 20 minutes.

Professor Yang Pengfei of the Cerebrovascular Disease Center at Changhai Hospital Conducts Animal Experiments

During Cerebral Angiography

“Performing surgery while seated is quite comfortable, and the control levers are very intuitive to use, much like my previous surgical experiences, requiring minimal changes to my established operative habits. Furthermore, the control precision is excellent, and the catheter-wire linkage function is highly useful, significantly improving the delivery efficiency of catheters and guidewires,” stated Professor Shen Li after completing the animal surgery.

Professor Shen Li from the Department of Cardiology at Shanghai Zhongshan Hospital Conducts Animal Experiments

 During Coronary Angiography

Previously, Shenzhen Aibo Medical Robot Co., Ltd. successfully completed preclinical animal studies of this product in Shenzhen and other regions, verifying the safety and efficacy of the device for interventional surgeries. During this series of animal surgery training sessions, expert teams led by Academician Ge Junbo from Shanghai Zhongshan Hospital and Professor Liu Jianmin from Changhai Hospital efficiently performed multiple cerebral angiography and coronary angiography procedures using the vascular interventional surgical operation system. They expressed high recognition of the company’s product for its unique capability in precise multi-instrument collaborative control, strong compatibility with guidewires and catheters, and its distinctive user-centered interaction design philosophy tailored for clinical users.

Shenzhen Aibo Medical Robot Co., Ltd. has consistently collaborated with clinical Principal Investigator (PI) teams to conduct ongoing animal studies, ensuring timely feedback from clinicians. Adhering to its product development philosophy of “From the doctor, By the engineer, For the patient,” the company is committed to balancing benefits for both operators and patients. On one hand, it continuously refines vascular interventional technologies for surgical robots, enhances procedural precision, controls costs, and optimizes its supply chain. On the other hand, it engages deeply in clinical settings to identify unmet needs, advances the automation and intelligence of its products, expands indications, and achieves full robotic execution of certain procedures. These efforts aim to reduce surgical preparation time and ensure the products align closely with surgeons’ operational habits.

 Aibo Vascular Interventional Robot System (Console)

The Company has established strategic medical-engineering collaborations with the team of Academician Ge Junbo from the Department of Cardiology at Zhongshan Hospital, Fudan University; the team of Professor Liu Jianmin from the Cerebrovascular Disease Center at Changhai Hospital, Naval Medical University; and the team of Professor Fu Weiguo from the Department of Vascular Surgery at Zhongshan Hospital, Fudan University. Together, they will deeply integrate clinical R&D resources centered on vascular interventional surgery scenarios to develop a pan-vascular interventional surgical robot system with greater clinical value and industry foresight, thereby meeting diverse clinical needs. The Company has already established a multi-pipeline product portfolio tailored to different surgical scenarios. As of October 2022, the Company had filed over 300 patents domestically and internationally, forming a comprehensive patent matrix. All technologies and designs possess fully independent intellectual property rights, positioning the Company favorably for future global market expansion.

As a pioneer in the field of pan-vascular interventional surgical robots, Academician Guo Shuxiang, co-founder of Shenzhen Aibo Medical Robot Co., Ltd., pioneered the development of the world’s first pan-vascular interventional surgical robot as early as 2008, which can be used for angiography and treatment of neurological, coronary, and peripheral vascular conditions. After years of technological iteration, the first-generation prototype completed China’s first human clinical neurointerventional surgery in 2017.

Aibo Medical Vascular Interventional Surgical Robot System

Shenzhen Aibo Medical Robot Co., Ltd.’s vascular interventional surgical robot is designed based on a modular concept, enabling rapid expansion of its product pipeline to address diverse surgical scenarios. As the first product officially enters the registration clinical trial phase, the company is poised to launch a more intelligent, compact, lightweight, and cost-effective pan-vascular interventional surgical robot system, jointly developed with clinical principal investigator (PI) teams.